autosomal dominant

Corneal Dystrophy, Subepithelial Mucinous

Clinical Characteristics
Ocular Features: 

This disorder, reported so far in a single family, is an anterior corneal dystrophy with onset in the first decade of life.  The frequency of epithelial erosions tended to subside during adolescence but visual acuity continued to decline secondary to subepithelial nodular opacities and a generalized haze most dense centrally. No geographic lines are present and cystic changes in the epithelium were absent.  Bowman layer and deeper stuctures of the cornea are unaffected. Patients may have 20/30 vision into the fifth decade but after that it may decrease into the 20/400 range.  EM revealed accumulations of subepithelial fibrillar material.  Light microscopy and immunohistochemistry showed the material to be chondroitin-4-sulfate and dermatan sulfate.

Systemic Features: 

No systemic disease association has been reported.

Genetics

In the single 3 generation family reported, the pattern of inheritance was consistent with autosomal dominant inheritance.  No locus or mutation has been reported.

Pedigree: 
Autosomal dominant
Treatment
Treatment Options: 

The usual treatment for acute corneal erosions might be beneficial but other treatments have not been reported.  Penetrating keratoplasty and superficial keratectomy have been used on several patients but followup is not available.

References
Article Title: 

Corneal Dystrophy, Recurrent Epithelial Erosions

Clinical Characteristics
Ocular Features: 

Individuals have the onset of recurrent corneal erosions as a result of as yet unknown disease processes.  Onset is in the first decade of life (even in the first year of life)  often with some subepithelial haze or blebs while denser centrally located opacities develop with time.  Erosions often are precipitated by relatively minor trauma and are often difficult to treat, lasting for up to a week.  Fortunately, the erosions become less frequent as patients age and may cease altogether by the fifth decade of life.

Systemic Features: 

No systemic disease is associated with ERED.

Genetics

The few reported families have all had an autosomal dominant pattern of inheritance.  So far no locus or molecular defect has been identified.

The clinical features of this condition are found in other corneal dystrophies and it is likely that at least some of the reported cases may have had other unrecognized corneal conditions.

Pedigree: 
Autosomal dominant
Treatment
Treatment Options: 

The usual corneal erosion treatment of hypertonic solutions, bandage patching, and lubricating ointments may be helpful for acute erosions.  No long term preventative treatment has been found effective.  Corneal transplants remain clear centrally although peripheral opacities may reappear within a few years.

References
Article Title: 

Franceschetti Hereditary Recurrent Corneal Erosion

Lisch W, Bron AJ, Munier FL, Schorderet DF, Tiab L, Lange C, Saikia P, Reinhard T, Weiss JS, Gundlach E, Pleyer U, Lisch C, Auw-Haedrich C. Franceschetti Hereditary Recurrent Corneal Erosion. Am J Ophthalmol. 2012 Mar 7. [Epub ahead of print].

PubMed ID: 
22402249

Corneal Dystrophy, Thiel-Behnke

Clinical Characteristics
Ocular Features: 

This type of anterior corneal dystrophy is genetically heterogeneous (caused by mutations in more than one locus). Recurrent corneal erosions are the main clinical feature and can begin in the first and second decades.  The epithelium is irregularly thickened while the Bowman layer and basal lamina of the basement membrane have degenerative changes which lead to the clinically evident honeycomb pattern of opacities.  Advanced changes in these tissues eventually leads to some vision loss.

The honeycomb pattern of degenerative changes in the corneal epithelium and Bowman membrane helps to distinguish this disorder from other anterior corneal dystrophies.  These are more prominent centrally with relative sparing of the juxtalimbal areas.  The epithelial basement membrane may be missing in some areas.  Histology is required for a definitive diagnosis with electron microscopy revealing characteristic 'curly' collagen fibrils in the subepithelial and anterior stromal tissues.  These degenerative changes tend to recur even after ablative procedures.

There is a great deal of clinical heterogeneity and the diagnosis is often unclear especially in younger individuals.  No doubt much of this is due to the fact that mutations in the major gene (TGFBI) responsible are also responsible for at least 5 other heritable corneal dystrophies and the argument can be made that all are variants of the same condition (vida infra).

Systemic Features: 

No systemic disease is associated with this corneal disease.

Genetics

Thiel-Behnke dystrophy is an autosomal dominant disorder.  However, it is genetically heterogeneous as mutations in at least two genes seem to produce the same phenotype. The majority of cases result from mutations in the TGFBI gene (5q31) but other corneal dystrophies (granular I or Groenouw type I, combined granular/lattice or Avellino type, Reis-Bucklers, epithelial basement membrane disease, and lattice type I) have mutations in the same gene.  This is a classic example of the variable expressivity of a single gene mutation characteristic of autosomal dominant disease. 

A second locus has been identified in a large 4 generation pedigree in which a presumed causative mutation was found on chromosome 10 (10q24). Some individuals in this family had evidence of two distinct types of dystrophies in the same cornea.  The responsible gene has not been identified. Genotyping is necessary to distinguish between the two disorders.

Pedigree: 
Autosomal dominant
Treatment
Treatment Options: 

Ablative treatments of the diseased cornea can be effective in reducing symptoms for extended periods but eventually the degenerative changes recur.  Acute erosions can be treated with hyperosmotic agents with some improvement.

References
Article Title: 

Reevaluation of corneal dystrophies of Bowman's layer and the anterior stroma (Reis-Bücklers and Thiel-Behnke types): a light and electron microscopic study of eight corneas and a review of the literature

Kuchle M, Green WR, Volcker HE, Barraquer J. Reevaluation of corneal dystrophies of Bowman's layer and the anterior stroma (Reis-Bucklers and Thiel-Behnke types): a light and electron microscopic study of eight corneas and a review of the literature. Cornea. 1995 Jul;14(4):333-54. Review.

PubMed ID: 
7671605

Corneal Dystrophy, Epithelial Basement Membrane

Clinical Characteristics
Ocular Features: 

The clinical appearance of the cornea in this disorder is non-specific with features found in as many as 75% of older individuals who do not have a corneal dystrophy. Some of the clinical findings are also found in other dystrophies such as Meesmann (122100), Reis-B?ocklers (608470), Lisch dystrophy (300778), lattice type I (122200), and Thiel-Behnke (602082).  The common feature in all these is the formation of microcysts in the epithelium with alterations in the basement membrane.  The pattern is sometimes described as a map-dot-fingerprint dystrophy.  Corneal erosions occur in all to some degree and vision is minimally impacted.  Many patients are asymptomatic unless corneal erosions occur.

Hereditary Cogan microcystic corneal dystrophy is sometimes diagnosed in the first decade of life but more characteristically found in people over the age of 30.  The corneal changes wax and wane and are highly variable between patients.  The dots consist of pseudocysts filled with intracellular debris while the geographic patterns are generated by multilayered basement membrane extensions into the epithelium.  The rupture of these cysts results in corneal erosions.  The underlying defect likely consists of defects in hemidesmosomal junctions.

Systemic Features: 

No systemic disease is associated with this corneal dystrophy.

Genetics

Many individuals with some findings of microcystic dystrophy have no family history of the disease and, as noted above, these are common in older people.  However, autosomal dominant pedigrees have been reported with typical corneal lesions among family members of all ages.  Several point mutations in the TGFBI gene on chromosome 5 (5q31) have been found but this likely accounts for only a small proportion of cases.  Mutations in the same gene have been found in other corneal dystrophies as well (lattice dystrophy I, granular dystrophy, Thiel-Behnke dystrophy, Reis-Bucklers, and combined lattice-granular dystrophy or Avellino type).

Genomic studies will likely clarify the current confusing nosology.

Pedigree: 
Autosomal dominant
Treatment
Treatment Options: 

Most patients require no treatment.  Persistent epithelial erosions can be treated with hypertonic solutions or bandage lenses.

References
Article Title: 

Corneal Dystrophy, Meesmann

Clinical Characteristics
Ocular Features: 

Meesmann corneal dystrophy is a disorder of the epithelium and its basement membrane.  Onset is early, even in the first year of life and begins with irritation and often photophobia.  However, some patients remain asymptomatic for many years.  Vision is usually impacted only to a mild degree as a result of surface irregularities and epithelial cysts, which are concentrated most commonly in the interpalpebral regions.  They may only be visible with slit lamp examination. The cysts are usually in the basal cells and are filled with PAS positive material. They may coalesce to form refractile lines and later in life become more opaque. The basement membrane appears coarse and is often abnormally thick.  Bowman layer and the stroma are unaffected.  Corneal sensitivity is reduced.

Stocker-Holt dystrophy (122100) is often lumped with Meesmann dystrophy and, while it is a clinically similar disease, it is usually caused by a different mutation.  The 20 patients reported by Stocker and Holt in 1954 were descendents from Moravia who settled in North Carolina (Meesmann and Wilke's report in 1939 was based on patients in Holstein, Germany).

Systemic Features: 

No systemic disease is associated with this dystrophy.

Genetics

This is a genetically heterogeneous autosomal dominant disorder resulting from mutations in several genes encoding cornea-specific keratins, K12 by KRT12 (similar to Stocker-Holt dystrophy; 122100) and K3 by KRT3 (Meesmann dystrophy) located on chromosomes 17 (q12) and 12 (q13), respectively.

 

Pedigree: 
Autosomal dominant
Treatment
Treatment Options: 

Contact lenses are poorly tolerated and keratoplasty is rarely indicated.  Treatment is largely directed at symptoms with hypertonic solutions and sometimes with epithelial debridement.  The cystic changes tend to recur following removal of the offending epithelium and even after corneal replacement.

The Arg135Thr mutation in the KRT12 gene found in the German family reported by Meesman and Wilke in 1939 (and a common founder mutation in Europe) can be selectively silenced in vitro by an allele-specific short interfering RNA (siRNA) suggesting a novel approach to therapy.

References
Article Title: 

Peters Anomaly

Clinical Characteristics
Ocular Features: 

Peters anomaly occurs as an isolated malformation but also as a feature of other syndromes.  It is often unilateral.  A wide variety of other ocular findings may occur with Peters anomaly as well. Here we limit our description to 'simple' Peters anomaly in which the findings are limited to the eye having the classic findings of adhesions of the iris to the posterior cornea and a central or paracentral corneal leukoma.  The lens may also be adherent to the cornea and is often opacified to some degree.  Descemet's membrane and portions of the posterior stroma are usually missing as well.  Glaucoma is frequently present.  Importantly, there is a wide range in the presentation of clinical features.

Systemic Features: 

Peters anomaly is a frequent feature of numerous syndromes, both ocular and systemic, among them the Peters-plus (261540) syndrome (sometimes called the Kivlin-Krause (261540) syndrome) and has been reported in a case with aniridia (106210).

Genetics

Isolated Peters anomaly usually occurs in an autosomal recessive pattern but autosomal dominant patterns have been reported as well.  The recessive disorder may be caused by a mutation in several genes, notably PAX6, PITX2CYP1B1, FOXC1, and FOXE3.  The latter gene is also mutated in anterior segment mesenchymal dysgenesis (107250) and congenital primary aphakia (610256).  The variety of clinical features are likely the result of a disruption in some common pathway or pathways.  Mutations in B3GALTL associated with the Peters-Plus syndrome have not been identified in isolated Peters anomaly.

This is a genetically and clinically heterogeneity condition as whole genome sequencing reveals numerous additional gene mutations in patients with both syndromic and isolated Peters anomaly.

PITX2 is also mutated in ring dermoid of the cornea (180550) and in Axenfeld-Rieger syndrome type 1 (180500).  PAX6 mutations also cause diseases of the cornea, fovea, optic nerve and iris.

Pedigree: 
Autosomal dominant
Autosomal recessive
Treatment
Treatment Options: 

Glaucoma is the most serious threat to vision on Peters anomaly but also the most difficult to treat.  Less than a third of patients achieve control of intraocular pressure even with the most vigorous combinations of therapy.  Corneal opacities can be treated with transplantation but the prognosis is often guarded when glaucoma is present.

From eye bank and other data, it has been estimated that 65% of penetrating keratoplasties in infants for visually significant congenital corneal opacities are performed in patients with Peters anomaly. 

References
Article Title: 

Whole exome sequence analysis of Peters anomaly

Weh E, Reis LM, Happ HC, Levin AV, Wheeler PG, David KL, Carney E, Angle B, Hauser N, Semina EV. Whole exome sequence analysis of Peters anomaly. Hum Genet. 2014 Sep 3. [Epub ahead of print].

PubMed ID: 
25182519

Macular Dystrophy, North Carolina

Clinical Characteristics
Ocular Features: 

North Carolina macular dystrophy is characterized by central macular defects that are present at birth but rarely progress. The fundus findings are highly variable and are usually more dramatic than expected from the visual acuity, which ranges from 20/40 to 20/200, with an average around 20/50. The clinical findings have been classified into different grades: In Grade I, fine drusen-like lesions at the level of the retinal pigmented epithelium are found in the central macular area. Grade II exhibits central confluent drusen with or without pigmentary changes, retinal pigment epithelium atrophy, disciform scar formation or neovascularization. Grade III is characterized by a well-delineated chorioretinal degeneration with hyperpigmentation at the border of the lesion. A central crater-like lesion that affects all retinal layers, as well as the deep choroidal tissue, is a typical finding. It is surrounded by an elevated ridge, which is 3-4 disc diameters size.  Color vision and electrophysiological testing are usually normal.

Some patients have choroidal neovascularization that may be responsive to anti-vascular endothelial growth factor treatment. 

Although first described in a 4 generation North Carolina family, it has since been found in a variety of ethnic groups and geographic locations.

Systemic Features: 

No general systemic manifestations are associated with North Carolina macular dystrophy.

Genetics

North Carolina macular dystrophy is an autosomal dominant disorder with high penetration.  One locus for the disorder, designated MCDR1 and containing a DNase 1 hypersensitivity site, has been mapped to 6q14-q16.2 and adversely impacts the retinal transcription factor gene PRDM13.  Multiple variants in this area have been identified.  However, other forms including MCDR2 (608051) resulting from mutations in PROM1 (4p15) and MCDR3 (608850) (linked to a locus at 5p13-p15) have been reported. 

The disorder was initially described in a family of Irish descent in North Carolina, and affected individuals have been identified in European, Asian and South American families as well.

Pedigree: 
Autosomal dominant
Treatment
Treatment Options: 

For patients with choroidal neovascularization, standard treatment for neovascularization may be used. Low vision aids can be useful for other forms of the disorder with decreased visual acuity.

References
Article Title: 

Lymphedema-Distichiasis Syndrome

Clinical Characteristics
Ocular Features: 

This form of lymphedema is associated with distichiasis, often with trichiasis and significant corneal damage in about 75% of patients.  Onset of symptoms may occur at any age but usually during childhood or adolescence.  Photophobia, epiphora, corneal erosions, ptosis, and partial ectropion of the lids may also be seen.  The secondary symptoms of trichiasis are not always present and slit lamp examination of the lashes may be necessary to see the duplicated row of lashes.  The lashes often grow out of the Meibomian orifices.

Systemic Features: 

Cardiac defects, cleft palate, and spinal extradural cysts occur in some families.  Type II diabetes and interstitial nephritis have been reported.  The lymph channels in the lower extremities may be normal or increased in number, especially below the knee where pitting edema is most often first seen, even as early as the first decade of life.  Lymphedema occurs earlier in males and secondary cellulitis is a greater risk. It is usually confined to the lower extremities and is often asymmetrical.  Not all patients have the complete syndrome, while lymphedema and distichiasis can be inherited as individual disorders without being associated.  Males are more likely to have the complete syndrome.

Several families with this syndrome secondary to mutations in the FOXC2 have been reported to have renal anomalies ranging from kidney agenesis to malrotation. 

Genetics

This disorder is inherited in an autosomal dominant pattern and several families have been found to have mutations in the FOXC2 gene on chromosome 16 (16q24.3).  A Chinese family with an affected father and two affected offspring (one male and one female) has been reported with distichiasis but no lymphedema.  A premature stop codon was found in the FOXC2 transcription gene (16q24.1) in these family members suggesting that they may have had the lymphedema-distichiasis syndrome instead.

Blatt distichiasis is a unique disorder without the lymphedema (126300). 

Double rows of eyelashes are also part of the blepharocheilodontic syndrome (119580).

Pedigree: 
Autosomal dominant
Treatment
Treatment Options: 

Electrolysis of individual misdirected lashes can be applied.  Prompt treatment of lid cellulitis is important. Surgical repair of scarred lid tissue can restore cosmesis lid function and improve cosmesis.

References
Article Title: 

Renal anomalies and lymphedema distichiasis syndrome

Jones GE, Richmond AK, Navti O, Mousa HA, Abbs S, Thompson E, Mansour S, Vasudevan PC. Renal anomalies and lymphedema distichiasis syndrome. A rare association? Am J Med Genet A. 2017 May;173(8):2251-2256.

PubMed ID: 
28544699

Hereditary lymphedema and distichiasis

Kolin T, Johns KJ, Wadlington WB, Butler MG, Sunalp MA, Wright KW. Hereditary lymphedema and distichiasis. Arch Ophthalmol. 1991 Jul;109(7):980-1.

PubMed ID: 
2064580

Corneal Dystrophy, Fuchs Endothelial, Late Onset

Clinical Characteristics
Ocular Features: 

There are a number of endothelial corneal dystrophies to which Fuchs name has been attached, including two that are early in onset, or even congenital (CHED1; 121700), (CHED2; 217700) and at least three that have an adult onset, one (Fuchs endothelial dystrophy, early onset; 136800) which has a relatively early onset and two considered to have a late onset: the one described here and another known as Fuchs Endothelial Dystropy, Late Onset 2 (613267).  Evidence for multiple distinct types comes from genotyping which reveals considerable genetic heterogeneity in spite of similar phenotypes (see Genetics).  All are progressive and degenerative with various degrees of visual disability.  Most have histologic changes in both the endothelial cells and Descemet membrane.

The entity described here likely is the classical disease described in the older literature.  It is certainly the most common, occurring in 4% of the population over the age of 40 years and for unknown reasons is more often found in females.  Guttae are formed as excrescences of Descemet's membrane and develop initially in the central cornea, beginning about the 5th decade, gradually increasing in number and size toward the periphery. They tend to be relatively large, sharply peaked and often positioned at the cell-cell junctions of endothelial cells.  These are often best visualized by corneal transillumination.  Histologically, the posterior portion of Descemet membrane contains bundles and sheets of abnormal collagen.  Progressive corneal edema follows as endothelial cells are lost and the remaining ones are unable to maintain normal stromal hydration.  Fingerprint lines may be present.  The corneal edema may involve both stroma and epithelium and in advanced stages may lead to painful epithelial erosions.  The disease is relentless and early blurring of vision progresses to significant visual handicaps often requiring corneal transplantation in the 7th and 8th decades.

Corneal guttae are common in older individuals but usually are located more peripherally.  The diagnosis of Fuchs can best be made where the guttae are concentrated centrally and associated with stromal and epithelial edema.

Systemic Features: 

No systemic abnormalities have been reported.

Genetics

Late onset Fuchs of this type is due to a mutation on chromosome 13 (13pter-q12.13) but the specific molecular basis for the disease remains unclear.  Many cases occur sporadically but some pedigrees are consistent with autosomal dominant inheritance.  For unknown reasons females are more commonly affected and often have more severe disease.  Recent reports suggest that missense mutations in ZEB1 may be responsible for at least some cases of late-onset Fuchs.  This mutation has also been found in cases of type 3 posterior polymorphous dystrophy (609141) suggesting that the two conditions may be allelic.

Other rare forms of late onset endothelial dystrophy to which the eponymic designation of Fuchs has been applied include FECD3 (613267) in which various mutations in the TCF4 locus on chromosome 18 (18q21.2-q21.3) (and expanded TGC trinucleotide repeats) have been implicated.  Other variants of Fuchs endothelial dystrophy include FECD4 (613268) with a mutation in SLC4A11 (20p13-p12), FECD5 (613269) with a possible mutation on chromosome 5 (5q33.1-q35.2), FECD6 (613270) due to a mutation in ZEB1 on chromosome 10 (10p11.2), and FECD7 (613271) that can be mapped to chromosome 9 (9p24.1-p22.1).

Pedigree: 
Autosomal dominant
Treatment
Treatment Options: 

Corneal transplantation has a good prognosis and posterior lamellar grafting may be the technique of choice.  In some patients, visually significant cataracts are present before the cornea is severely involved and a triple procedure may be considered.  However, this is best determined by pachymetry.  Individuals with a preoperative corneal thickness of even >600 micrometers can do well after cataract surgery for a number of years before the cornea needs to be replaced.

References
Article Title: 

E2-2 protein and Fuchs's corneal dystrophy

Baratz KH, Tosakulwong N, Ryu E, Brown WL, Branham K, Chen W, Tran KD, Schmid-Kubista KE, Heckenlively JR, Swaroop A, Abecasis G, Bailey KR, Edwards AO. E2-2 protein and Fuchs's corneal dystrophy. N Engl J Med. 2010 Sep 9;363(11):1016-24.

PubMed ID: 
20825314

Corneal Dystrophy, Fuchs Endothelial, Early Onset

Clinical Characteristics
Ocular Features: 

This is one of several adult onset corneal endothelial dystrophy (see Fuchs endothelial corneal dystrophy, late onset, (610158) for more forms of adult Fuchs endothelial dystrophy).  The onset of this type is considerably earlier than in the more common adult onset type (610158) .  Endothelial disease has been noted as early as three years of age but onset is likely later than in the congenital forms (CHED1; 121700), (CHED2; 217700).  In early onset Fuchs dystrophy, most individuals have evident disease by the third and fourth decades and many have advanced disease by the fourth and fifth decades.  The sex ratio among affected individuals is closer to 1:1 in this disorder compared with the more common adult onset type in which the disease is more common in females.

In this early onset disorder the guttae are small and more rounded than those in the later onset endothelial dystrophies, and are closer to the center of the endothelial cells.  The progression of corneal decompensation is temporally similar to that of the late onset dystrophies, resulting in clinically advanced disease within 3 to 4 decades.  The progression of disease has been documented through quantifying the number of guttae over time.   Among 26 patients, the number increased as much as 29.1% over a 30 month period, and an exponential increase was noted after age 50 years.  The inferotemporal quadrant of the cornea had the greatest proportion of guttae.  As in other forms of endothelial corneal dystrophy, Descement's  membrane is thickened and exhibits nodularity with secondary apoptosis of endothelial cells.

Systemic Features: 

None have been reported.

Genetics

A mutation in the COL8A2 gene, L450W, located on chromosome 1 (1p34.3-p32.3) seems to be responsible for this disease.  The gene codes for the alpha-2 chain of collagen VIII which is an important component of Descemet's membrane.  Like many other collagen diseases, this disorder is transmitted as an autosomal dominant.

This gene is also mutant in posterior polymorphous corneal dystrophy 2 (609140) and both types of dystrophy have been reported in the same family suggesting they may be the same disorder with variable expressivity.

Pedigree: 
Autosomal dominant
Treatment
Treatment Options: 

Corneal transplantation is the treatment of choice for advanced disease.

References
Article Title: 

Missense mutations in COL8A2,the gene encoding the alpha2 chain of type VIII collagen, cause two forms of corneal endothelial dystrophy

Biswas S, Munier FL, Yardley J, Hart-Holden N, Perveen R, Cousin P, Sutphin JE, Noble B, Batterbury M, Kielty C, Hackett A, Bonshek R, Ridgway A, McLeod D,Sheffield VC, Stone EM, Schorderet DF, Black GC. Missense mutations in COL8A2,the gene encoding the alpha2 chain of type VIII collagen, cause two forms of corneal endothelial dystrophy. Hum Mol Genet. 2001 Oct 1;10(21):2415-23.

PubMed ID: 
11689488

Inheritance of Fuchs' combined dystrophy

Magovern M, Beauchamp GR, McTigue JW, Fine BS, Baumiller RC. Inheritance of Fuchs' combined dystrophy. Ophthalmology. 1979 Oct;86(10):1897-923.

PubMed ID: 
399801

Pages

Subscribe to RSS - autosomal dominant